AIR’s early childhood cost and finance team informs state decisions about the true cost of high-quality early care and education, the systems that support it, and revenue sources that can fund it. Our work has focused on childcare subsidies, different preschool models, and support for birth-to-five children with special needs. ...
AIR has played a critical role in investigating the use of evidence-based practices in home visiting, early language outcomes, home visiting during the COVID-19 pandemic, and evaluations of the Welcome Baby program sponsored by First 5 LA.
This spotlight takes a look at the history of Title I, how the program has changed over time, and how it affects children, schools, families and education policy. Experts weigh in on the program's past and future in interviews, briefs, and blogs.
The COVID pandemic has profoundly disrupted U.S. healthcare. AIR leverages our expertise in data analysis, technical assistance, human-centered design and stakeholder engagement to understand disparities associated with COVID-19 morbidity and mortality and support hospitals serving vulnerable populations. ...
More than 45 million Americans live in rural areas. Rural residents often encounter barriers to healthcare, including provider shortages or traveling long distances. AIR leverages expertise in data analysis, technical assistance, human-centered design and stakeholder engagement to understand and help solve the healthcare challenges facing rural communities. ...
Signed into law in 2015, the Every Student Succeeds Act (ESSA) is a commitment by Congress and the U.S. Department of Education to equal educational opportunity for all American students. As states continue to implement ESSA programs, AIR is providing a series of action guides to support and inform education ...
Millions of Americans can’t afford their prescription drugs and often resort to skipping doses or going without critical medications. AIR works with clients at the federal, state, and local levels to identify and implement policies to reduce the cost burden of prescription drugs for patients.